361 related articles for article (PubMed ID: 15816500)
21. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
Gesek FA; Desmond JS
Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
[TBL] [Abstract][Full Text] [Related]
22. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
Wolf M; Thadhani R
Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
[TBL] [Abstract][Full Text] [Related]
23. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
26. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
[TBL] [Abstract][Full Text] [Related]
27. Are vitamin D receptor activators useful for the treatment of thrombosis?
Wu-Wong JR
Curr Opin Investig Drugs; 2009 Sep; 10(9):919-27. PubMed ID: 19705334
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
[TBL] [Abstract][Full Text] [Related]
30. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
[TBL] [Abstract][Full Text] [Related]
31. Role of vitamin D deficiency in chronic kidney disease.
Gal-Moscovici A; Sprague SM
J Bone Miner Res; 2007 Dec; 22 Suppl 2():V91-4. PubMed ID: 18290730
[TBL] [Abstract][Full Text] [Related]
32. The dual vitamin D pathways: considerations for adequate supplementation.
Cronin SC
Nephrol Nurs J; 2010; 37(1):19-26, 36; quiz 27-8. PubMed ID: 20333900
[TBL] [Abstract][Full Text] [Related]
33. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
34. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.
Brancaccio D; Cozzolino M; Cannella G; Messa P; Bonomini M; Cancarini G; Caruso MR; Cascone C; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
Blood Purif; 2011; 32(2):124-32. PubMed ID: 21625082
[TBL] [Abstract][Full Text] [Related]
35. Role of vitamin D in cardiovascular disease.
Verhave G; Siegert CE
Neth J Med; 2010 Mar; 68(3):113-8. PubMed ID: 20308705
[TBL] [Abstract][Full Text] [Related]
36. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment.
Cuppari L; Garcia-Lopes MG
J Ren Nutr; 2009 Jan; 19(1):38-43. PubMed ID: 19121769
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulating effects of vitamin D analogs in hemodialysis patients.
Seibert E; Levin NW; Kuhlmann MK
Hemodial Int; 2005 Oct; 9 Suppl 1():S25-9. PubMed ID: 16223440
[TBL] [Abstract][Full Text] [Related]
38. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
39. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.
Raggi P; Kleerekoper M
Clin J Am Soc Nephrol; 2008 May; 3(3):836-43. PubMed ID: 18322050
[TBL] [Abstract][Full Text] [Related]
40. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
